MedTrace Logo

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

NCT06679816 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 882

Last updated 2025-01-14

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are:

• Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency.

Participants will:

* Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks
* Visit the clinic three months after surgery for checkups and tests
* Keep a diary of their symptoms

Conditions

  • Pituitary Adenoma
  • Pituitary Neuroendocrine Tumor

Interventions

DRUG

Hormone replacement therapy

Perioperative Hydrocortisone Reduction Therapy

DRUG

Placebo

Perioperative placebo Reduction Therapy

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06679816 on ClinicalTrials.gov